MK-0524A Approval Status
FDA Approved: No
Brand name: MK-0524A
Generic name: niacin ER and laropiprant
Previous Name: Cordaptive
Company: Merck & Co., Inc.
Treatment for: Hyperlipoproteinemia Type IIa, Elevated LDL, Hypertriglyceridemia
MK-0524A is an investigational compound containing extended-release niacin and laropiprant, a novel flushing pathway inhibitor designed to reduce flushing often associated with niacin treatment. MK-0524A is intended for use either alone or with a statin, as adjunctive therapy to diet for the treatment of elevated LDL cholesterol, low HDL cholesterol and elevated triglyceride levels.
In April 2008, Merck announced the receipt of a Not Approvable Letter from the U.S. Food and Drug Administration (FDA) advising the company that the New Drug Application (NDA) for MK-0524A had not been approved.
Development Status and FDA Approval Process for MK-0524A
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
